The Health and Human Services Department on Monday unveiled two policies that it said will enhance transparency and reduce “unnecessary” regulation on drugs and medical devices.

Executives at several pharmaceutical companies that received government funding for coronavirus vaccines have made $105 million in stock sales since this fall, according to a report by Accountable Pharma first shared with POLITICO.

What’s happening: From September to mid-November, top employees at four drug companies involved in coronavirus vaccine development (Emergent BioSolutions, Moderna, Novavax and Pfizer) made a net profit of $105 million. That follows a busy summer: A previous Accountable report found that executives at those four plus Johnson & Johnson made $145 million on stock sales.